Budget impact of Paxlovid

Name: Budget impact of Paxlovid
Creator: Núcleo de Avaliação de Tecnologias em Saúde Instituto Nacional de Cardiologia
Published: 2026-04-09T12:25:56+08:00

Mendeley Data2026-04-09 收录

药物经济学评估

公共卫生预算分析

数据链接：

https://data.mendeley.com/datasets/gvnhbw6m7k 数据链接链接失效反馈

官方服务：

资源简介：

Analysis of the Budgetary impact of paxlovid for the treatment of adults who do not require supplemental oxygen and who are at increased risk for progression to severe coronavirus disease 2019 (COVID-19) in Brazil Health System

提供机构：

Núcleo de Avaliação de Tecnologias em Saúde Instituto Nacional de Cardiologia

Incremental Costs, Revenues and Outcomes with PCSK9 (Per Patient. Health System’s and Payer’s Perspective) 1/ .

药物经济学评估

心血管治疗成本分析

Incremental Costs, Revenues and Outcomes with PCSK9 (Per Patient. Health System’s and Payer’s Perspective) 1/.

NIAID Data Ecosystem30

Healthcare resource utilization and expenditures among newly-diagnosed elderly non-valvular atrial fibrillation patients initiating oral anticoagulants

药物经济学评估

心血管病治疗优化

Aims: Non-valvular atrial fibrillation (NVAF) prevalence increases with age. Hence, evaluating the economic burden among older-aged patients is vital. This study aimed to compare healthcare res

Taylor & Francis Group2024-02-28 更新10

The heterogeneity in the cost per case avoided with coxibs stratified by the number of major risk factors and exposure characteristics (with the cost per case avoided estimated for each individual prescription).

药物经济学评估

临床用药优化

#Each NSAID prescription was classified according to first-ever use, long gap (previous prescription at least 6 mo before), and short gap (previous prescription within the last 6 mo). The medication p

Figshare2015-12-02 更新10

Table 1_Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: network meta-analysis and budget impact analysis.docx

药物经济学评估

COVID-19治疗

IntroductionRemdesivir (RDV) and nirmatrelvir/ritonavir (NRM/RTV) are two antiviral agents for treating outpatient adults with mild to moderate symptomatic COVID-19 at high risk of developing a severe

NIAID Data Ecosystem10

Differences in healthcare resource utilization and direct medical costs of patients with rheumatoid arthritis (RA) before and after the use of multiple biologic agents-Switched.

药物经济学评估

类风湿关节炎治疗管理

Differences in healthcare resource utilization and direct medical costs of patients with rheumatoid arthritis (RA) before and after the use of multiple biologic agents-Switched.

Figshare2018-07-18 更新10

Budget impact of Paxlovid

资源简介：

相关数据集